These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14586401)

  • 21. Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas.
    Thornber K; Colomba A; Ceccato L; Delsol G; Payrastre B; Gaits-Iacovoni F
    Oncogene; 2009 Jul; 28(29):2690-6. PubMed ID: 19503098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of NPM-ALK interacting proteins by tandem mass spectrometry.
    Crockett DK; Lin Z; Elenitoba-Johnson KS; Lim MS
    Oncogene; 2004 Apr; 23(15):2617-29. PubMed ID: 14968112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?
    Turner SD; Alexander DR
    Leukemia; 2005 Jul; 19(7):1128-34. PubMed ID: 15902287
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.
    Mourali J; Bénard A; Lourenço FC; Monnet C; Greenland C; Moog-Lutz C; Racaud-Sultan C; Gonzalez-Dunia D; Vigny M; Mehlen P; Delsol G; Allouche M
    Mol Cell Biol; 2006 Aug; 26(16):6209-22. PubMed ID: 16880530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches.
    Wasik MA; Zhang Q; Marzec M; Kasprzycka M; Wang HY; Liu X
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S27-35. PubMed ID: 19393833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
    Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
    Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
    Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G
    Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death.
    Hollmann CA; Owens T; Nalbantoglu J; Hudson TJ; Sladek R
    Cancer Res; 2006 Apr; 66(7):3550-7. PubMed ID: 16585179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
    Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
    Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated levels of PtdIns5P in NPM-ALK transformed cells: implication of PIKfyve.
    Coronas S; Lagarrigue F; Ramel D; Chicanne G; Delsol G; Payrastre B; Tronchère H
    Biochem Biophys Res Commun; 2008 Jul; 372(2):351-5. PubMed ID: 18501703
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin II activates the human renin promoter in an in vitro model: the role of c-Jun-N-terminal kinase.
    Terebessy T; Masszi A; Fintha A; Sebe A; Huszár T; Rosivall L; Mucsi I
    Nephrol Dial Transplant; 2004 Sep; 19(9):2184-91. PubMed ID: 15238629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
    Palmby TR; Abe K; Karnoub AE; Der CJ
    Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
    Passoni L; Longo L; Collini P; Coluccia AM; Bozzi F; Podda M; Gregorio A; Gambini C; Garaventa A; Pistoia V; Del Grosso F; Tonini GP; Cheng M; Gambacorti-Passerini C; Anichini A; Fossati-Bellani F; Di Nicola M; Luksch R
    Cancer Res; 2009 Sep; 69(18):7338-46. PubMed ID: 19723661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.
    Vishwamitra D; Curry CV; Alkan S; Song YH; Gallick GE; Kaseb AO; Shi P; Amin HM
    Mol Cancer; 2015 Feb; 14():53. PubMed ID: 25884514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
    Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R
    Cancer Res; 2008 Nov; 68(21):8899-907. PubMed ID: 18974134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
    Giuriato S; Foisseau M; Dejean E; Felsher DW; Al Saati T; Demur C; Ragab A; Kruczynski A; Schiff C; Delsol G; Meggetto F
    Blood; 2010 May; 115(20):4061-70. PubMed ID: 20223922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice.
    Kuefer MU; Look AT; Pulford K; Behm FG; Pattengale PK; Mason DY; Morris SW
    Blood; 1997 Oct; 90(8):2901-10. PubMed ID: 9376569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaplastic lymphoma kinase proteins in growth control and cancer.
    Pulford K; Morris SW; Turturro F
    J Cell Physiol; 2004 Jun; 199(3):330-58. PubMed ID: 15095281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming.
    Marzec M; Halasa K; Liu X; Wang HY; Cheng M; Baldwin D; Tobias JW; Schuster SJ; Woetmann A; Zhang Q; Turner SD; Ødum N; Wasik MA
    J Immunol; 2013 Dec; 191(12):6200-7. PubMed ID: 24218456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner.
    Cui YX; Kerby A; McDuff FK; Ye H; Turner SD
    Blood; 2009 May; 113(21):5217-27. PubMed ID: 19286999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.